Pain Therapeutics, Inc. Late Stage Drugs For Mega-Markets

Remi Barbier, CEO of South San Francisco based-Pain Therapeutics (PTIE), is driven by the desire to put new treatments on the market. As COO of Exelixis, he thought the discovery platform was "sexy", but realized that clinical development was a long way off. So he decided to found Pain Therapeutics, with the idea of starting at the end of drug development rather than the beginning of drug discovery, where risks are lower and rewards potentially larger. This featured company profile is part of a special issue of Neurotech Insights focused on Pain.

Back to news